Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 6/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039431 | 0.85 | GCGR (0.48) | GCGRHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL13963500 | 0.84 | PIK3CD (0.36) | GCGRSMN1; SMN2ALDH1A1RAB9AMEN1 | |
| SCHEMBL4040868 | 0.83 | GCGR (0.48) | GCGRMAPK10HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4039739 | 0.78 | GCGR (0.51) | GCGRMAPK10SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL4040586 | 0.73 | GCGR (0.51) | GCGRHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL4045910 | 0.71 | GCGR (0.60) | GCGRHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL4037149 | 0.70 | MEN1 (0.57) | GCGRMAPK10SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL2648246 | 0.69 | GCGR (0.54) | GCGRSMN1; SMN2ALDH1A1RAB9APOLB | |
| SCHEMBL4040577 | 0.68 | GCGR (0.59) | GCGRHTTSMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL2647695 | 0.68 | HPGD (0.47) | GCGRHTTSMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549655-B1 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | claimed |
| US-7273876-B2 | Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1549655-A4 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050239865-A1 | Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | claimed |
| EP-1549655-A2 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004024065-A2 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | claimed |
| EP-1549655-B1 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7273876-B2 | Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273876-B2 | Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273876-B2 | Substituted bicylic thiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20050239865-A1 | Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239865-A1 | Substituted bicyclic thiophene derivatives, compositions containing such compounds and methods of use | GLP1R, GCGR, GPR119 | GCGR 2/4885MAPK10 2263/4885HTT 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.